Related Experiment Video
Updated: Jul 10, 2026
04:08
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
Published on: January 18, 2021
Rhythmic auditory stimulation modulates gait variability in Parkinson's disease.
Jeffrey M Hausdorff1, Justine Lowenthal, Talia Herman
1Laboratory for Gait and Neurodynamics, Movement Disorders Unit and Parkinson Center, Department of Neurology, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel. jhausdor@bidmc.harvard.edu
The European Journal of Neuroscience
|October 24, 2007
Summary
Rhythmic auditory stimulation (RAS) can improve gait in Parkinson's disease (PD) patients by reducing stride-to-stride variability, a key fall risk factor. These improvements suggest potential for RAS as a therapeutic intervention for mobility and fall prevention in PD.
Area of Science:
- Neurology
- Movement Disorders
- Rehabilitation Science
Background:
- Parkinson's disease (PD) is characterized by gait impairments, including reduced stride length and increased stride-to-stride variability, which are linked to fall risk.
- Rhythmic auditory stimulation (RAS) is known to improve stride length in PD patients, but its impact on stride-to-stride variability remains unclear.
Purpose of the Study:
- To investigate the effects of RAS on stride time and swing time variability, as well as other spatiotemporal gait parameters, in individuals with idiopathic PD.
- To assess whether RAS-induced improvements in gait variability persist after the stimulation stops (carryover effects).
Main Methods:
- 29 patients with idiopathic PD and 26 healthy controls underwent 100-m walks with RAS set at 100% and 110% of their usual cadence.
- Stride time variability, swing time variability, and spatiotemporal gait measures were analyzed.
- Carryover effects of RAS were evaluated at 2 and 15 minutes post-intervention.
Main Results:
- Patients with PD exhibited significantly higher gait variability than controls during usual walking.
- RAS at 100% cadence improved gait speed, stride length, and swing time in PD patients, but not variability.
- RAS at 110% cadence significantly reduced gait variability in PD patients, with effects persisting for up to 15 minutes.
- RAS did not yield similar benefits in healthy controls and even increased variability in some cases.
Conclusions:
- RAS at 110% cadence enhances automaticity and reduces gait variability in Parkinson's disease patients, independent of speed or stride length changes.
- The observed carryover effects suggest potential motor plasticity in the neural networks controlling rhythmicity in PD.
- RAS demonstrates promise as a non-pharmacological intervention to improve mobility and mitigate fall risk in individuals with Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...